What compounds target IP6K1?

BiohacksAI has identified 20 compounds that interact with IP6K1 (inositol hexakisphosphate kinase 1). Top compounds include: Edaravone, Disulfiram, Febuxostat, Hydroxyzine, Suramin. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is IP6K1 (inositol hexakisphosphate kinase)?

IP6K1 is inositol hexakisphosphate kinase 1. It is a molecular target for 20 compounds documented in PubMed bioassay data. NCBI Gene ID: 9807.

IP6K1

MOLECULAR TARGET

inositol hexakisphosphate kinase 1

NCBI Gene: 980720 compounds

IP6K1 (inositol hexakisphosphate kinase 1) is targeted by 20 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting IP6K1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	Edaravone	1.61	4
2	Disulfiram	1.39	3
3	Febuxostat	1.39	3
4	Hydroxyzine	1.39	3
5	Suramin	1.39	3
6	Methylene Blue	1.10	2
7	Resveratrol	1.10	2
8	Demeclocycline	1.10	2
9	Diiodotyrosine	1.10	2
10	Ethidium	1.10	2
11	Ethylestrenol	1.10	2
12	Idazoxan	1.10	2
13	Lysergic Acid Diethylamide Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is	1.10	2
14	Mestranol	1.10	2
15	monorden	1.10	2
16	Nitrofurazone	1.10	2
17	Tetracycline	1.10	2
18	Apigenin 5,7,4'-trihydroxy-flavone,	0.69	1
19	myricetin-3-O-galactopyranoside [Supplementary Concept]	0.69	1
20	Aurintricarboxylic Acid	0.69	1

About IP6K1 as a Drug Target

IP6K1 (inositol hexakisphosphate kinase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 20 compounds with documented IP6K1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

IP6K1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.